Arlene Chapman to Pain
This is a "connection" page, showing publications Arlene Chapman has written about Pain.
Connection Strength
0.870
-
Quality of life in autosomal dominant polycystic kidney disease patients not yet on dialysis. Clin J Am Soc Nephrol. 2009 Mar; 4(3):560-6.
Score: 0.281
-
Patient-reported outcome measures for pain in autosomal dominant polycystic kidney disease: A systematic review. PLoS One. 2021; 16(5):e0252479.
Score: 0.164
-
Establishing a Core Outcome Set for Autosomal Dominant Polycystic Kidney Disease: Report of the Standardized Outcomes in Nephrology-Polycystic Kidney Disease (SONG-PKD) Consensus Workshop. Am J Kidney Dis. 2021 02; 77(2):255-263.
Score: 0.155
-
Tolvaptan and Kidney Pain in Patients With Autosomal Dominant Polycystic Kidney Disease: Secondary Analysis From a Randomized Controlled Trial. Am J Kidney Dis. 2017 Feb; 69(2):210-219.
Score: 0.120
-
Core Outcome Domains for Trials in Autosomal Dominant Polycystic Kidney Disease: An International Delphi Survey. Am J Kidney Dis. 2020 09; 76(3):361-373.
Score: 0.038
-
Range and Variability of Outcomes Reported in Randomized Trials Conducted in Patients With Polycystic Kidney Disease: A Systematic Review. Am J Kidney Dis. 2020 08; 76(2):213-223.
Score: 0.038
-
Effect of Tolvaptan in Autosomal Dominant Polycystic Kidney Disease by CKD Stage: Results from the TEMPO 3:4 Trial. Clin J Am Soc Nephrol. 2016 05 06; 11(5):803-811.
Score: 0.029
-
Health-related quality of life in patients with autosomal dominant polycystic kidney disease and CKD stages 1-4: a cross-sectional study. Am J Kidney Dis. 2014 Feb; 63(2):214-26.
Score: 0.024
-
Rationale and design of the TEMPO (Tolvaptan Efficacy and Safety in Management of Autosomal Dominant Polycystic Kidney Disease and its Outcomes) 3-4 Study. Am J Kidney Dis. 2011 May; 57(5):692-9.
Score: 0.020